# Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

> **NCT02926937** · PHASE3 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 399 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sotagliflozin (SAR439954)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02926937
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-11
- **Primary completion:** 2019-04-22
- **Final completion:** 2019-05-17
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2021-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02926937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02926937, "Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02926937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*